251 related articles for article (PubMed ID: 15935070)
1. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
Li W; Lee MK
J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070
[TBL] [Abstract][Full Text] [Related]
2. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.
Flower TR; Chesnokova LS; Froelich CA; Dixon C; Witt SN
J Mol Biol; 2005 Sep; 351(5):1081-100. PubMed ID: 16051265
[TBL] [Abstract][Full Text] [Related]
3. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C; Vernier P; Sidhu A
Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560
[TBL] [Abstract][Full Text] [Related]
4. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
5. Dopamine-related and caspase-independent apoptosis in dopaminergic neurons induced by overexpression of human wild type or mutant alpha-synuclein.
Zhou ZD; Yap BP; Gung AY; Leong SM; Ang ST; Lim TM
Exp Cell Res; 2006 Jan; 312(2):156-70. PubMed ID: 16297908
[TBL] [Abstract][Full Text] [Related]
6. Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death.
Kaul S; Anantharam V; Kanthasamy A; Kanthasamy AG
Brain Res Mol Brain Res; 2005 Sep; 139(1):137-52. PubMed ID: 15978696
[TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
[TBL] [Abstract][Full Text] [Related]
8. Lack of alpha-synuclein does not alter apoptosis of neonatal catecholaminergic neurons.
Stefanis L; Wang Q; Oo T; Lang-Rollin I; Burke RE; Dauer WT
Eur J Neurosci; 2004 Oct; 20(7):1969-72. PubMed ID: 15380020
[TBL] [Abstract][Full Text] [Related]
9. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.
Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G
FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691
[TBL] [Abstract][Full Text] [Related]
11. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
12. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
13. Embryonic stem cell-derived neuron models of Parkinson's disease exhibit delayed neuronal death.
Yamashita H; Nakamura T; Takahashi T; Nagano Y; Hiji M; Hirabayashi T; Amano T; Yagi T; Sakai N; Kohriyama T; Matsumoto M
J Neurochem; 2006 Jul; 98(1):45-56. PubMed ID: 16805795
[TBL] [Abstract][Full Text] [Related]
14. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
15. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
[TBL] [Abstract][Full Text] [Related]
16. Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death.
Vekrellis K; Xilouri M; Emmanouilidou E; Stefanis L
J Neurochem; 2009 Jun; 109(5):1348-62. PubMed ID: 19476547
[TBL] [Abstract][Full Text] [Related]
17. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
18. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
[TBL] [Abstract][Full Text] [Related]
19. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.
Mishizen-Eberz AJ; Norris EH; Giasson BI; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
Biochemistry; 2005 May; 44(21):7818-29. PubMed ID: 15909996
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants of PLD2 inhibition by alpha-synuclein.
Payton JE; Perrin RJ; Woods WS; George JM
J Mol Biol; 2004 Apr; 337(4):1001-9. PubMed ID: 15033366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
